News Releases

Tuesday, July 21, 2015

U.S. News ranks University Hospitals Case Medical Center among nation's best hospitals

 
CLEVELAND – University Hospitals Case Medical Center once again has been recognized as one of the nation's best hospitals by U.S. News & World Report. UH Case Medical Center was ranked among the country’s top 50 in nine methodology-ranked specialties. The annual U.S. News Best Hospitals rankings, now in their 26th year, recognize hospitals that excel in treating the most challenging patients.
 
The recent data underscores UH Case Medical Center’s elite, national standing as a leader in clinical care as less than 3 percent of the nearly 5,000 hospitals that were analyzed for Best Hospitals 2015-16 earned national ranking in even one specialty. UH Case Medical Center is nationally ranked in: Cancer; Cardiology & Heart Surgery; Ear, Nose & Throat; Gastroenterology and GI Surgery; Geriatrics; Nephrology; Neurology & Neurosurgery; Orthopaedics; and Urology.


Wednesday, July 08, 2015

UH Seidman Cancer Center investigators develop activated T cell therapy for advanced melanoma

CLEVELAND – T cells from patients with melanoma can trigger a protective immune response against the disease according to a new study out of University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine.
 
Published in the July/August issue of Journal of Immunotherapy, these new findings demonstrate that T cells derived from lymph nodes of patients with melanoma can be expanded in number and activated in the laboratory for intravenous administration in the treatment of patients.  Led by Julian Kim, MD, Chief Medical Officer at UH Seidman Cancer Center, the research team has developed a novel technique to generate large numbers of activated T cells which can be transferred back into the same patient to stimulate the immune system to attack the cancer.
 
“This study is unique in that the source of T cells for therapy is derived from the lymph node, which is the natural site of the immune response against pathogens as well as cancer,” says Dr. Kim who is also Professor of Surgery at Case Western Reserve University School of Medicine and the Charles Hubay Chair at UH Case Medical Center. “These encouraging results provide the rationale to start testing the transfer of activated T cells in a human clinical trial.”
t; font-family:"Arial","sans-serif"'>Anthem and UH announced in December 2014 a commercial Accountable Care Organization (ACO) designed to improve the overall quality of care while lowering the overall cost of health care. This new Accountable Care Organization for Medicare will leverage and expand upon the current relationship and market-leading infrastructure to coordinate care through high-quality providers to positively impact Anthem MA members’ health and wellness. The enhanced personal health care arrangement brings high-quality, patient-centered care to patients, and helps to control costs by promoting greater preventive care, enhanced care coordination and effective chronic disease management.
 
“University Hospitals is pleased to join with Anthem on this new accountable care arrangement that will enhance health services and improve coordination of care for Anthem’s Medicare Advantage members,” said Paul Tait, UH Chief Strategic Planning Officer. “As a national leader in population health management, we have had great success in improving health, enhancing quality of care, and managing costs for patients in our accountable care programs and we look forward to serving Anthem Medicare members.”


Wednesday, July 08, 2015

University Hospitals Cleveland, Anthem Blue Cross and Blue Shield announce patient-centered primary care collaboration for Medicare

CLEVELAND University Hospitals (UH) in Cleveland and Anthem Blue Cross and Blue Shield have launched a patient-centered arrangement designed to lower the cost of health care while improving overall quality for members in Medicare Advantage (MA) in Northeast Ohio.
 
Anthem and UH announced in December 2014 a commercial Accountable Care Organization (ACO) designed to improve the overall quality of care while lowering the overall cost of health care. This new Accountable Care Organization for Medicare will leverage and expand upon the current relationship and market-leading infrastructure to coordinate care through high-quality providers to positively impact Anthem MA members’ health and wellness. The enhanced personal health care arrangement brings high-quality, patient-centered care to patients, and helps to control costs by promoting greater preventive care, enhanced care coordination and effective chronic disease management.
 
“University Hospitals is pleased to join with Anthem on this new accountable care arrangement that will enhance health services and improve coordination of care for Anthem’s Medicare Advantage members,” said Paul Tait, UH Chief Strategic Planning Officer. “As a national leader in population health management, we have had great success in improving health, enhancing quality of care, and managing costs for patients in our accountable care programs and we look forward to serving Anthem Medicare members.”


Wednesday, July 01, 2015

Sujana Biotech, a new biotech start-up, is launched by BioMotiv

CLEVELAND – BioMotiv, LLC (“BioMotiv”) a drug development accelerator associated with The Harrington Project for Discovery & Development – centered at University Hospitals in Cleveland, Ohio – announces the formation of Sujana Biotech, LLC, (“Sujana Biotech”) a company developing novel technologies and therapeutic products for a range of inflammatory and vascular disorders. 

The technology, licensed from Case Western Reserve University, is based on seminal research by scientific founders Daniel Simon, MD, President, University Hospitals Harrington Heart & Vascular Institute, and Herman K. Hellerstein, Chair of Cardiovascular Research and Professor of Medicine, Case Western Reserve University School of Medicine, Edward Plow, PhD, Chair of the Department of Molecular Cardiology, and Robert C. Tarazi, MD, Endowed Chair in Heart and Hypertension Research, Cleveland Clinic, and Yunmei Wang, PhD, Research Scientist and Assistant Professor of Medicine, Case Western Reserve University School of Medicine.  These scientists identified a unique binding site on the leukocyte integrin Mac-1 that is responsible for the pathologic recruitment and activation of leukocytes at sites of vascular injury.


Monday, June 29, 2015

Mevion Medical Systems delivers proton accelerator to Seidman Cancer Center at University Hospitals

CLEVELAND – Mevion Medical Systems is annoucing the delivery of the superconducting synchrocyclotron accelerator for its MEVION S250 proton therapy system under installation at University Hospitals (UH) Seidman Cancer Center and UH Rainbow Babies & Children’s Hospital in Cleveland.

The accelerator, which is the core of the proton therapy system, was delivered Friday. Its installation is a crucial step in the deployment of the proton therapy system at UH. The unit will be the first proton therapy system in Ohio treating adult and pediatric cancer patients when it begins clinical operation in the spring of next year. This is the sixth accelerator delivery for Mevion, the innovator behind the world’s most efficient and cost-effective high-precision proton therapy system.



You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.